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sleep deprivation; VEH, vehicle solution; W, wakefulness.is available regarding the neurobiological role of the endo-
cannabinoid system in the homeostatic control of sleep. 
Therefore, the aim of the current experiment was to test if 
SR141716A, URB597 or VDM-11 would modulate the sleep 
rebound after sleep deprivation. Thus, these compounds 
were systemically injected (5, 10, 20 mg/kg; ip; separately 
each one) into rats after prolonged waking. We found that 
SR141716A and URB597 blocked in dose-dependent fashion 
the sleep rebound whereas animals treated with VDM-11 dis-
played sleep rebound during the recovery period. Comple-
mentary, injection after sleep deprivation of either 
SR141716A or URB597 enhanced dose-dependently the 
extracellular levels of dopamine (DA), norepinephrine (NE), 
epinephrine (EP), serotonin (5-HT), as well as adenosine 
(AD) while VDM-11 caused a decline in contents of these 
molecules. These ﬁndings suggest that SR141716A or 
URB597 behave as a potent stimulants since they sup-
pressed the sleep recovery period after prolonged waking. 
It can be concluded that elements of the endocannabinoid 
system, such as the CB1 cannabinoid receptor, FAAH and 
AMT, modulate the sleep homeostasis after prolonged 
waking. 
Key words: alertness, sleep deprivation, microdialysis, REM
sleep, serotonin, HPLC.
INTRODUCTION
The neurobiological actions of endogenous cannabinoid-
like compounds have been described from molecular to
behavioral approaches (Pertwee, 2006, 2015; Scherma
et al., 2014; Katona, 2015; Lutz et al., 2015; Manduca
et al., 2015; Velasco et al., 2015; Lu and Mackie, 2016;
Nikan et al., 2016; Wang et al., 2016). Since anandamide
was the very ﬁrst endocannabinoid described (Devane
et al., 1992), it has been the focus of attention due to that
it resembles the pharmacological eﬀects of principal
compound of Cannabis sativa, D9-THC, by behaving as
a natural ligand for the CB1 cannabinoid receptor
(Console-Bram et al., 2012). Among the evidence regard-
ing the role of activation of the CB1 cannabinoid receptor
modulating diverse functions controlled by the central ner-
vous system, it has been demonstrated that administra-
tions of anandamide promote sleep (Murillo-Rodrı´guez
et al., 1998, 2001, 2003; Herrera-Solis et al., 2010;
Rueda-Orozco et al., 2010), whereas injections of the
CB1 cannabinoid receptor antagonist SR141716A
increase alertness in rodents (Santucci et al., 1996;
Murillo-Rodrı´guez et al., 2001, 2003).
To elucidate the neurobiological properties of other
elements belonging to the endocannabinoid system,
such as anandamide’s major metabolic enzyme Fatty
Acid Amide Hydrolase (FAAH), several studies have
been aimed to describe the eﬀects of FAAH in multiple
experimental paradigms (Chauvet et al., 2015; Fowler,
2015; Panlilio et al., 2016), including experiments in
sleep. For instance, FAAH-KO mice display no signiﬁcant
diﬀerences in sleep rebound after prolonged waking ses-
sions (Huitro´n-Rese´ndiz et al., 2004) whereas studies
outline that levels of expression of FAAH are lower in
the brain after sleep deprivation in naı¨ve animals (Wang
et al., 2011). In addition, pharmacological experiments
using the FAAH inhibitor named URB597, have shown
that injections of this compound enhance wakefulness
(W) and decrease slow wave sleep (SWS) as well as
rapid eye movement sleep (REMS) in rats (Murillo-
Rodrı´guez et al., 2007, 2011).
An additional actor of the endocannabinoid system
includes the anandamide membrane transporter (AMT)
which displays a key role in modulating anandamide’s
biological functions (Chicca et al., 2012; Fowler, 2013;
Khasabova et al., 2013; Leung et al., 2013; Nicolussi
and Gertsch, 2015). The available evidence indicates that
injections of blocker of AMT known as VDM-11 promote
sleep in rats (Murillo-Rodrı´guez et al., 2008, 2013). To
sum up, convincing available data suggest that CB1
cannabinoid receptors, FAAH and AMT may contribute
to sleep control. However, the role of these molecular
mediators in the regulation of sleep homeostasis has
been scantly described so far.
In the last decades, accumulating reports have
suggested that the sleep–wake cycle is under control of
a complex neurobiological network which includes
neuroanatomical, neurochemical and molecular
components (Murillo-Rodrı´guez et al., 2012; Zeitzer,
2013; Saper, 2013; Fernandes et al., 2015; Schwartz
and Kilduﬀ, 2015). In parallel, further complicatedness in
the understanding of sleep mechanism has been
pointed-out due to that circadian and homeostatic factors
inﬂuence sleep processes (Curie et al., 2013, 2015;
Houben et al., 2014; Borbely et al., 2016). In regard to
the homeostatic clout in sleep modulation and consistent
with previous reports, it is known that a compensatory
enhancement in the intensity and duration of sleep known
as ‘‘sleep rebound” is present as a result of signiﬁcative
loss of sleep (Borbely and Achermann, 1999; Schwierin
et al., 1999; Ocampo-Garces et al., 2000; Vyazovskiy
et al., 2007, 2011; Borbely et al., 2016). Additionally, the
total sleep deprivation (TSD) is accompanied with an
accumulation of endogenous neurochemicals, including
dopamine (DA), norepinephrine (NE), epinephrine (EP),
serotonin (5-HT), as well as adenosine (AD). As part of
the sleep homeostasis, animals that are allowed to sleep
once TSD is over show a diminishing proﬁle in the con-
tents of several neurochemicals (Porkka-Heiskanen
et al., 2000, 2002; Lena et al., 2005; Zant et al., 2011;
Brown et al., 2012). In spite of the ﬁndings of the eﬀects
of the endocannabinoids in sleep modulation, noevidence is available regarding its inﬂuence in sleep
homeostasis control. Thus, in particular, it is important
to assess whether SR141716A, URB597 or VDM-11
would modulate sleep homeostasis as well as neuro-
chemicals related with sleep after prolonged waking.
EXPERIMENTAL PROCEDURES
Experiment 1: blockade of sleep rebound by
SR141716A, URB597 or VDM-11 injection after total
sleep deprivationAnimals. Male Wistar rats (n= 20; 250–300 g) were
singly housed in polycarbonate cages
(48.26 cm  26.67 cm  20.32 cm; Harlan Laboratories.
Me´xico) under light–dark cycle (lights-on: 07:00–
19:00 h), humidity controlled (60 ± 10%) and constant
temperature (21 ± 1 C). In all time, rats had free
access to Purina Rat Chow (Purina. Me´xico) as well as
tap water. The experimental protocols were approved by
the Research and Ethics Committee of our University
fulﬁlling the domestic and international standards of
animal welfare including the Mexican Standards Related
to Use and Management of Laboratory Animals (DOF.
NOM-062-Z00-1999) as well as the National Institutes of
Health (NIH publication No. 80-23, revised 1996).
During the whole study, eﬀorts to minimize animal
suﬀering were considered and for ethical reasons, it
used a reduced number of animals.
Chemicals. Compounds such as SR141716A (CAS
Number: 158681-13-1), URB597 (CAS Number 546141-
08-6) and VDM-11 (CAS Number 313998-81-1) were
purchased from Sigma–Aldrich (St Louis, MO. USA).
These chemicals were dissolved in a vehicle (VEH)
solution composed of polyethylglycol/saline (5:95 v/v) as
described previously (Murillo-Rodrı´guez et al., 2003,
2011, 2013). All reagents, chemicals, and materials were
purchased from Sigma–Aldrich (St Louis, MO. USA).
Sleep-recording surgeries. Animals (n= 10) were
anesthetized by a mixture of acepromazine (0.75 mg/kg),
xylazine (2.5 mg/kg), and ketamine (22 mg/kg) and
placed in a stereotaxic frame (David Kopf Instruments.
Tujunga, CA. USA) for sleep-recording electrodes
implantation. Two stainless-steel screw electrodes were
inserted 2 mm on either side of the sagittal sinus and
3 mm anterior to Bregma (frontal cortex) whereas other
two screws were located 3 mm on either side of the
sagittal sinus and 6 mm behind Bregma (occipital
cortex). This setting recorded the electroencephalogram
(EEG) signal by the bipolar (diﬀerential) EEG recorded
from two contralateral screw electrodes (frontal–
occipital). In regard to the recording of the
electromyogram (EMG), this signal was obtained by the
implantation of two wire electrodes into the dorsal neck
muscles in each rat. Next, EEG/EMG wires were
inserted into a six-pin plastic plug (Plastics One.
Roanoke, VA. USA) and they were secured onto the
skull by commercial dental cement. Upon completion of
the EEG/EMG surgeries, the rats were placed into
individual cages with regular bedding and standard water
and food containers. Animals were connected to a 6-
channel slip-ring commutator through a 50-cm cable
(Plastics One. Roanoke, VA. USA), which allowed rats
free turning and moving around in the box during post-
operative recovery period. The surgical procedure as
well as habituation conditions (during 7 days) were
carried out as reported elsewhere (Murillo-Rodrı´guez
et al., 2011).
Sleep recordings analysis. The EEG/EMG data were
scored in 12 s epochs characterizing W, SWS or REMS
by the sleep-scoring program (ICELUS). Brieﬂy, the
EEG/EMG wires were connected to the slip-ring system
(Plastics One. Roanoke, VA. USA) and to the ampliﬁer
which ﬁltered the EEG signal at 70 Hz (low-pass ﬁlter)
and 0.3 Hz (high-pass ﬁlter; Model M15LT 15A54; Grass
Instruments. Quincy, MA. USA). The signals were
continuously sampled at 128 Hz using a 100-bit analog-
to-digital converter board (NI PCI-6033E Multifunction
I/O Board and NI-DAQ Software, SCB-100 Shielded
Connector Block. National Instruments. Austin, TX.
USA). The sleep–wake cycle was characterized as
follows: The waking state was identiﬁed by the presence
of desynchronized EEG and high EMG activity whereas
SWS consisted of high-amplitude slow waves together
with a low EMG tone relative to awake. Lastly, REMS
was determined by the presence of regular theta activity
coupled with low EMG relative to SWS. The entire
sleep-recordings analysis procedure was followed as
previously reported (Mijangos-Moreno et al., 2016).
Immediately after 6 h of TSD, experimental treatments
were given to rats and sleep data were obtained during
the following 4 h and analyzed as previously reported
(Murillo-Rodrı´guez et al., 2011, 2013).
Total sleep-deprivation. Prolonged waking was
carried out by maintaining rats on constant alertness
across 6 h (from 07:00–13:00 h) by stroking fur with an
artist’s paintbrush, provoking light noise near the cages
or by tapping or placing novel objects into the cages
(Arias-Carrio´n et al., 2011). During the TSD, sleep data
were constantly recorded and analyzed as reported
(Murillo-Rodrı´guez et al., 2011).
Pharmacological administrations. Right after the end
of TSD, animals were disconnected from the sleep-
recording system and experimental trials were
administered during the lights-on period randomly as
follows: VEH, SR141716A, URB597 or VDM-11 (5, 10,
20 mg/kg, i.p.; n= 10 each group). Irrespective of
whether the injection of VEH could modify the sleep–
wake cycle, an additional group named ‘‘sham” (n= 10)
was included in the experimental design. This group
consisted in animals that received the insertion (i.p.) of
the needle but no administration was given. To avoid
possible accumulative pharmacological eﬀects, animals
were under a ‘‘wash out period” which consisted in 24 h
period between treatments. Once experimental
challenges were given, rats were reattached to the
sleep-recording system and sleep data were collectedacross the next 4 h. Sleep stages were obtained across
4 h (hour-1, hour-2, hour-3 and hour-4) post-treatments
during the sleep recovery period. Next, we averaged the
four time points as a total value for each state of
vigilance (W, SWS or REMS) in every experimental
condition. Then, these total values were included in the
corresponding statistical analysis. Lastly, in the current
experiment, treatments were done randomly using a
single-blind Latin Square Experimental Design. Since
each subject serves as its own control, the testing
paradigm has the advantage of decreasing variability
among experimental conditions.
Statistical analysis. Data were represented as mean
± standard error of the mean. Statistical diﬀerences
were determined by a one-way ANOVA followed by
Scheﬀe´’s post hoc test for multiple comparisons. All
statistical analyses were performed using the StatView
(version 5.0.0, SAS Institute. USA) and statistical
diﬀerences among groups were determined if P< 0.05.
Experiment 2: eﬀects of SR141716A, URB597 or VDM-
11 on neurochemical levels during the sleep rebound
after 6 h of prolonged wakingAnimals. A new set of rats was employed for this part
of the study. All animals were housed as described in
Experiment 1.
Chemicals. All compounds as described in
Experiment 1.
Microdialysis surgeries. Experiments have
demonstrated the critical role of nucleus accumbens
(AcbC) in sleep control (Lazarus et al., 2012, 2013; Qiu
et al., 2012; Zhang et al., 2013; Liu et al., 2016). More-
over, previous work from our laboratory has provided reli-
able measurements of monoamines and AD from AcbC
(Murillo-Rodrı´guez et al., 2006; Mijangos-Moreno et al.,
2014, 2016). Thus, these previous evidence allowed us
to consider AcbC as candidate for microdialysis sampling.
To achieve this goal, a new set of animals (n= 10) was
anesthetized and placed into the stereotaxic frame (David
Kopf Instruments. Tujunga, CA. USA) for implantation of a
microdialysis guide-cannula (IC guide; BioAnalytical Sys-
tems [BAS]. West Lafayette, IN. USA) which was unilater-
ally placed into the AcbC (coordinates: A =+1.2 and
L =+2.0, H = 7.0 mm, with reference to Bregma
[Paxinos and Watson, 2005]). After the surgery, animals
were placed individually into the microdialysis bowl
(Raturn Microdialysis Stand-Alone System. MD-1404.
BAS. West Lafayette, IN. USA) for recovery as well as
habituation for the experimental conditions during 7 days.
All surgical procedures were accomplished as previously
reported (Mijangos-Moreno et al., 2014, 2016).
Microdialysis sampling procedures. One week after
microdialysis surgery the stylet from guide-cannula was
withdrawn and microdialysis probe (1 mm of length;
polyacrylonitrile, MWCO= 30,000 Daltons; 340 lm OD;
BAS. West Lafayette, IN. USA) was inserted at 07:00 h.
Artiﬁcial cerebrospinal ﬂuid (aCSF [composition: NaCl
147 mM, KCl 3 mM, CaCl 1.2 mM, MgCl 1.0 mM, pH
7.2]) was continuously perfused through a minitube
(0.65 mm OD  0.12 mm ID; BAS. West Lafayette, IN.
USA) attached to a 2.5 mL syringe (BAS. West
Lafayette, IN. USA) using a pump (ﬂow rate: 0.25 lL/min;
BAS Bee. West Lafayette, IN, USA). On the other hand,
previous experiments have found that after insertion, the
microdialysis probe requires 6–7 h for stabilization
(Porkka-Heiskanen et al., 2000; Murillo-Rodrı´guez et al.,
2004), in the present report, the probes were stabilized
during 24 h in freely moving rats. Once stabilization period
was achieved and right after the sleep deprivation period,
microdialysis samples were collected hourly from each
animal starting at 13:00 h across the lights-on period over
4 h (dialysates were collected the ﬁrst 20 min of every
hour). Next, samples were averaged over the four time
points as a total value for each compound in every exper-
imental condition (sham, VEH, SR141716A, URB597 and
VDM-11; separately all doses for each drug). Thus, these
total values were included in the corresponding statistical
analysis. Therefore, the reported data represent the aver-
age of hourly concentration over a period of time of 4 h of
sampling from each molecule. However, an example of
the time course, of at least one of the neuromodulators,
during the total sleep deprivation (six samples taken at
hourly intervals) and the sleep recovery period (four sam-
ples taken at hourly intervals) was analyzed. In addition,
the microdialysis probes were used no more than 5 days
since precedent studies have reported that subsequently
insertion, gliosis diminishes the membrane ability to trans-
port ﬂuid across the pores (Porkka-Heiskanen et al.,
2000; Murillo-Rodrı´guez et al., 2004). For the in vitro
recovery data, aCSF solution was perfused at the ﬂow
rate of 0.25 lL/min into the microdialysis probe, which
was inserted into the test solution containing external
known concentrations of monoamines or AD. The same
sampling procedure was repeated using a diﬀerent lot of
microdialysis probes. Later, each sample collected from
in vitro recovery study was analyzed and the peak area
ratio was calculated against the known standards. To
obtain the recovery rate, data were calculated as follows:
Recovery rate (%) = (the peak area ratio of the sample
from microdialysis sample)/(the peak area ratio of the
sample in the test solution). Further details of microdialy-
sis procedures are available in previous reports (Porkka-
Heiskanen et al., 2000; Blanco-Centurion et al., 2006;
Murillo-Rodrı´guez et al., 2007, 2011; Mijangos-Moreno
et al., 2014, 2016).Sleep deprivation procedure. As described in
Experiment 1.Pharmacological challenge. Twenty-four hours after
stabilization of microdialysis probes, TSD was carried
out from 07:00 to 13:00 h. Once the prolonged waking
session ﬁnished, animals were disconnected from
microdialysis system and treatments were randomly
given during the lights-on period as described in
Experiment 1. Right after the experimental challenges
were provided, animals were reattached to themicrodialysis system and samples were collected across
4 h and stored (80 C) for further analysis.High-performance liquid chromatography (HPLC).
The collected dialysates were injected into HPLC for
detection and quantiﬁcation of DA, NE, 5-HT or AD.
Brieﬂy, the dialysates were ﬁltered (Millipore 0.22 lm;
Merck Millipore. Darmstadt, Germany) and injected into
HPLC (Modular Prominence, Shimadzu. Japan). The
mobile phase (monosodium phosphate [7 mM, pH 3.0],
plus methanol [3.5%]) was perfused at a ﬂow rate of
80 lL/min using a pump (LC-20AT, Shimadzu, Japan)
and the separation of molecules was achieved using a
microbore column (octadecyl silica [3 lm, 100  1 mm].
BAS, West Lafayette, IN, USA). To further determine
the contents of DA, NE, 5-HT or AD in the microdialysis
samples, a series of dilutions of known external
standards for monoamines or AD were prepared. The
method to ensure the speciﬁcity was developed
following the instructions provided by the manufacturer
as well as reported by others (Sartori et al., 2008;
Mazzucchelli et al., 2011). Detection of monoamines car-
ried out using an electrochemical detector (LC-4C; BAS.
West Lafayette. IN, USA) as described by others (Gold
et al., 2011; Grupe et al., 2013) whereas AD was detected
using an UV detector (SPD-20A, Shimadzu. Japan) set to
a wavelength of 254 nm (deuterium lamp). All chromato-
graphic data were recorded in a personal computer, and
peak heights of neurochemicals in dialysates were com-
pared with external standards using chromatograph
report software (LC Solution, Shimadzu. Japan). All pro-
cedures for detection and measurement of monoamines
or AD were developed according to previous reports
(Murillo-Rodrı´guez et al., 2011; Mijangos-Moreno et al.,
2014, 2016).Histological verification of probe location. After
microdialysis experiments, all animals were
anesthetized with a lethal dose of pentobarbital for the
standard procedure for the vascular perfusion. Rats
were transcardially perfused through a ventricular
catheter placed on the left ventricle. Next, the right
atrium was cut open and saline solution (0.9%) followed
by formaldehyde (4%) were perfused. The brain was
removed and post-ﬁxed overnight in formaldehyde (4%)
followed by 30% sucrose/0.1 M PBS for 48 h. Last, all
brains were cut in coronal sections (20 lm) using a
Portable Bench-top Cryostat (Leica CM1100. Germany)
and collected in 1:5 serial order. One serial was used
for probe location and it was identiﬁed by plotting using
rat brain atlas (Paxinos and Watson, 2005).Statistical analysis. Data from microdialysis
experiments were represented as mean ± standard
error of the mean. The statistical analyses were
performed by StatView program (version 5.0.0, SAS
Institute, USA) and statistical signiﬁcances were
determined by a one-way ANOVA followed by Scheﬀe´’s
post hoc test for multiple comparisons. Values of
P< 0.05 were considered as statistically signiﬁcant.
RESULTS
Experiment 1: blockade of sleep rebound by
SR141716A, URB597 or VDM-11 injection after total
sleep deprivation
As expected, no statistical diﬀerences were found between
sham and VEH groups in total time of W, SWS or REMS
after TSD (Panel A, Panel B, Panel C, respectively).
However, it was found that during the sleep rebound
period, and compared to respective control group,
administrations of SR141716A (5, 10, 20 mg/kg) causeda dose-dependent enhancement in alertness (Fig. 1,
Panel A; F (4, 45) = 2630.75; P< 0.0001) as well as a
decrease in SWS (Fig. 1, Panel A; F (4, 45) = 453.69;
P< 0.0001) and REMS (Fig. 1, Panel A; F (4, 45) =
120.35; P< 0.0001). It was found that SR141716A
behaved as a potent stimulant since promoted alertness
during the sleep rebound period after 6 h of prolonged
waking. Similar, but not identical ﬁndings were observed
comparing to control/sham rats in URB-treated animals
(5, 10, 20 mg/kg) since a blocking eﬀect in the sleep
rebound was observed by increasing alertness (Fig. 1,
Panel B; F (4, 45) = 175.262; P< 0.0001) and
diminishing in a dose-dependent fashion SWS (Fig. 1,
Panel B; F (4, 45) = 102.790; P< 0.0001) and REMS
(Fig. 1, Panel B; F (4, 45) = 356.884; P< 0.0001).
Despite these fascinating results, URB597 was not able
to induce a signiﬁcant dose-dependent eﬀect in W and
REMS. Moreover, it is noteworthy that this compound
blocked the sleep rebound of either SWS or REMS after
6 h of TSD in more potent fashion that SR141716A. This
data indicate the eﬀectiveness of URB597 by promoting
W after sleep deprivation. Reversed results were found
when VDM-11 (5, 10, 20 mg/kg) was injected in sleep-
deprived rats. For instance, no diﬀerences were found
among control/sham groups in W (Fig. 1, Panel C;
F (4, 45) = 0.00; P> 0.05), SWS (Fig. 1, Panel C;
F (4, 45) = 3.191; P> 0.05) as well as REMS (Fig. 1,
Panel C; F (4, 45) = 4.493; P> 0.05). This drug did not
block the sleep rebound in rats subjected to TSD. Taken
together, our data suggest that the CB1 cannabinoid
receptor, FAAH and AMT play a role in the modulation of
sleep homeostasis after sleep deprivation.Experiment 2: eﬀects of SR141716A, URB597 or VDM-
11 on neurochemical levels during the sleep rebound
after 6 h of prolonged waking
It is widely known that prolonged waking induces
endogenous accumulation of several neurochemicals
such as monoamines and purines whereas during theFig. 1. Eﬀects of pharmacological manipulation of the endocannabi-
noid system in wakefulness (W), slow wave sleep (SWS) or rapid eye
movement (REMS) during the sleep rebound period in sleep-deprived
rats. Panel A shows the eﬀects of administration of SR141716A (10,
20 or 30 mg/kg, i.p.) after total sleep deprivation period. As noted,
SR141716A enhanced in dose-dependent fashion W (F (4,
45) = 2630.75; P> 0.0001) and decreased SWS (F (4, 45) = 453.69;
P> 0.0001) and REMS (F (4, 45) = 120.35; P> 0.0001;
* vs Control/
VEH, P< 0.0001; # vs SR-10 (SR141716A, 10 mg/kg, i.p.), & vs SR-
20 (SR141716A, 20 mg/kg, i.p.). On the other hand, the eﬀects on
sleep rebound of FAAH inhibition using URB597 (10, 20 or 30 mg/kg, i.
p.) are shown in Panel B. As indicated, URB597 blocked the sleep
rebound by enhancing W (F (4, 45) = 175.262; P> 0.0001)
and diminishing SWS (F (4, 45) = 102.790; P> 0.0001) and REMS
(F (4, 45) = 356.884; P> 0.0001) during the sleep rebound period
(*vs Control/VEH, P< 0.0001; ¥ vs URB-10 (URB597, 10 mg/kg,
i.p.), – vs URB-20 (URB597, 20 mg/kg, i.p.). Lastly, the administration
of VDM-11 (10, 20 or 30 mg/kg, i.p.) after total sleep deprivation
caused no statistical eﬀects on W (F (4, 45) = 0.00; P> 0.05), SWS
(F (4, 45) = 3.191; P> 0.05) or REMS (F (4, 45) = 4.493; P> 0.05)
during the sleep rebound period. All comparisons determined by a
one-way ANOVA followed by Scheﬀe´s post hoc where P< 0.001
considered statistically diﬀerent.
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sleep rebound period, the contents of these molecules are
decreased (Porkka-Heiskanen et al., 2000, 2002; Lena
et al., 2005; Blanco-Centurion et al., 2006; Monti and
Jantos, 2008; Mohammed et al., 2011; Brown et al.,
2012). Thus, the rationale of the following experiment
was based to test whether SR141716A, URB597 or
VDM-11 would modulate the extracellular contents of DA,
NE, EP, 5-HT or AD after prolonged waking. We assessed
the eﬀects of the drugs on contents of these neurochemi-
cals after sleep deprivation by microdialysis and HPLC
means. First, levels of DA were not statistically diﬀerent
during TSD among groups (Fig. 2, Panel A; F (4, 45) =Fig. 2. Eﬀects of pharmacological activation or blockade of the endocannabin
prolonged waking. Levels of dopamine were enhanced after 6 h of prolonged
administration of either vehicle, SR141716A, URB597 or VDM-11 after prolon
contents were analyzed. Panel B shows that SR141716A enhanced in a d
P< 0.0001;* vs Control/VEH, # vs SR-10 (SR141716A, 10 mg/kg, i.p.), & v
after injection of URB597 (Panel C; F (4, 45) = 1951.791; P< 0.0001
* vs
(URB597, 20 mg/kg, i.p.). As indicated in Panel D, VDM-11 promoted a dim
Control/VEH, a vs VDM-10 (VDM-11, 10 mg/kg, i.p.), € vs VDM-20 (VDM-11
followed by Scheﬀe´’s post hoc where P< 0.001 considered statistically diﬀe0.587; P> 0.05). However, during sleep rebound period
and compared to control/sham groups, animals that
received SR141716A promoted the endogenous accumu-
lation of DA in a dose-dependent fashion (Fig. 2, Panel B;
F (4, 45) = 220.725; P< 0.0001). Moreover, injections of
URB597 induced a dose-dependent enhancement in the
contents of DA (Fig. 2, Panel C; F (4, 45) = 1951.791;
P< 0.0001). Nonetheless, administrations of VDM-11 at
diﬀerent doses (5, 10 or 20 mg/kg, i.p.) decreased the con-
tents of DA (Fig. 2, Panel D; F (4, 45) = 82.179;
P< 0.0001). Comparing the pharmacological eﬀects of
the compounds tested after TSD, we conclude thatoid system in the extracellular levels of dopamine in response to 6 h of
waking (Panel A; F (4, 45) = 0.587; P> 0.05). Next, rats received the
ged waking (10, 20 or 30 mg/kg; i.p. each compound) and dopamine
ose-dependent fashion the levels of dopamine (F (4, 45) = 220.725;
s SR-20 (SR141716A, 20 mg/kg, i.p.). Similar results were observed
Control/VEH, ¥ vs URB-10 (URB597, 10 mg/kg, i.p.), – vs URB-20
inution in contents of dopamine (F (4, 45) = 82.179; P< 0.0001;
* vs
, 20 mg/kg, i.p.). All comparisons determined by a one-way ANOVA
rent.
Fig. 3. Eﬀects of SR141716A, URB597 or VDM-11 (10, 20 or 30 mg/kg; i.p. each compound) on extracellular levels of norepinephrine after 6 h of
prolonged waking. Panel A shows that after 6 h or total sleep deprivation, contents of norepinephrine were enhanced (F (4,45) = 0.521; P< 0.05).
When animals received SR141716A immediately after prolonged waking, it was found an increase in a dose-dependent fashion the contents of
norepinephrine (Panel B; F (4, 45) = 15258.779; P< 0.0001;
* vs Control/VEH, # vs SR-10 (SR141716A, 10 mg/kg, i.p.), & vs SR-20 (SR141716A,
20 mg/kg, i.p.). URB597 caused similar results (Panel C; F (4,4 5) = 29135.400; P< 0.0001;
* vs Control/VEH, ¥ vs URB-10 (URB597, 10 mg/kg, i.
p.), – vs URB-20 (URB597, 20 mg/kg, i.p.). Finally, injections of VDM-11 decreased the levels of norepinephrine (Panel D; F (4, 45) = 7.185;
P< 0.0001;* vs Control/VEH, a vs VDM-10 (VDM-11, 10 mg/kg, i.p.), € vs VDM-20 (VDM-11, 20 mg/kg, i.p.). All comparisons determined by a one-
way ANOVA followed by Scheﬀe´’s post hoc where P< 0.001 considered statistically diﬀerent.URB597 displayed more potent response in promotion of
the endogenous accumulation of DA whereas VDM-11
induced opposite outcomes.
After injection of drugs, interesting results in the levels
of NE were found during the sleep rebound period. For
example, during TSD no statistical diﬀerences were
found in contents of NE among groups (Fig. 3, Panel A;
F (4, 45) = 0.521; P>0.05). Nevertheless, administrations
of SR141716A before the sleep rebound period enhanced
the levels of NE in a dose-dependent fashion (Fig. 3,
Panel B; F (4, 45) = 15258.779; P< 0.0001). Moreover,
URB597-treated rats displayed a dose-dependent
enhancement in the contents of NE (Fig. 3, Panel C;
F (4, 45) = 29135.400; P<0.0001) whereas the injectionsof VDM-11 at diﬀerent doses (5, 10 or 20 mg/kg, i.p.)
decreased NE levels (Fig. 3, Panel D; F (4, 45) = 7.185;
P< 0.0001). It is important to mention that only the
highest dose of VDM-11 decreased signiﬁcantly the
extracellular levels of NE. It is concluded that URB597
showed the most potent eﬀects by increasing the
accumulation of NE compared to SR141716A whereas
VDM-11 promoted contrary eﬀects.
After measuring the endogenous levels of EP during
prolonged waking, we found no statistical diﬀerences
among groups (Fig. 4, Panel A; F (4, 45) = 0.95; P>0.05).
However, administrations of SR141716A caused a
dose-dependent enhancement of contents of EP after TSD
(Fig. 4, Panel B; F (4, 45) = 134.970; P<0.0001) whereas
Fig. 4. Eﬀects of SR141716A, URB597 or VDM-11 (10, 20 or 30 mg/kg; i.p. each compound) on extracellular contents of epinephrine collected by
microdialysis after 6 h of prolonged waking. In response to total sleep deprivation, animals showed an increase in the extracellular levels of
epinephrine after total sleep deprivation (Panel A; F (4, 45) = 0.95; P> 0.05). However, when animals received SR141716A, we found a robust
enhancement in epinephrine levels (Panel B; F (4, 45) = 134.970; P< 0.0001;
* vs Control/VEH, # vs SR-10 (SR141716A, 10 mg/kg, i.p.), & vs
SR-20 (SR141716A, 20 mg/kg, i.p.). Moreover, URB597 promoted similar results (Panel C; F (4,45) = 164.245; P< 0.0001;
* vs Control/VEH, ¥ vs
URB-10 (URB597, 10 mg/kg, i.p.), – vs URB-20 (URB597, 20 mg/kg, i.p.) whereas administration of VDM-11 caused opposite eﬀects (Panel D;
F (4,45) = 36.977; P< 0.0001;
* vs Control/VEH, a vs VDM-10 (VDM-11, 10 mg/kg, i.p.), € vs VDM-20 (VDM-11, 20 mg/kg, i.p.). All comparisons
determined by a one-way ANOVA followed by Scheﬀe´’s post hoc where P< 0.001 considered statistically diﬀerent.injections of URB597 caused a dose-dependent decrease in
EP levels after prolonged waking (Fig. 4, Panel C;
F (4, 45) = 164.245; P<0.0001). Likewise, during sleep
rebound period, animals that received VDM-11 showed a
diminishing eﬀects on the extracellular contents of EP
(Fig. 4, Panel D; F (4, 45) = 36.977; P<0.0001). As shown
in the respective Figures, SR141716A and URB597
caused similar eﬀects by enhancing the levels of EP during
sleep rebound period whereas VDM-11 decreased
signiﬁcantly the contents of this neurotransmitter after
prolonged waking.Analysis of the 5-HT levels during TSD showed no
statistical diﬀerences among the experimental groups
(Fig. 5, Panel A; F (4, 45) = 0.592; P>0.05). Albeit
fascinating results were observed since SR141716A
enhanced in a dose-dependent fashion the contents of 5-
HT (Fig. 5, Panel B; F (4, 45) = 1678.310; P<0.0001).
Likewise, administrations of URB597 provoked a dose-
dependent increase in the levels of 5-HT after TSD
(Fig. 5, Panel C; F (4, 45) = 1522.333; P<0.0001).
Lastly, contents of 5-HT were found diminished in a dose-
dependent fashion after VDM-11 injection during sleep
Fig. 5. Eﬀects of SR141716A, URB597 or VDM-11 (10, 20 or 30 mg/kg; i.p. each compound) on levels of 5-HT collected after 6 h of prolonged
waking. Panel A shows that extracellular levels of 5-HT were enhanced after total sleep deprivation (F (4, 45) = 0.592; P> 0.05). However, when
rats received SR141716A, the levels of 5-HT were increased in a dose-dependent fashion (Panel B; F (4, 45) = 1678.310; P< 0.0001;
* vs Control/
VEH, # vs SR-10 (SR141716A, 10 mg/kg, i.p.), & vs SR-20 (SR141716A, 20 mg/kg, i.p.). Similar results were observed in URB597-treated rats
(Panel C; F (4, 45) = 1522.333; P< 0.0001;
* vs Control/VEH, ¥ vs URB-10 (URB597, 10 mg/kg, i.p.), – vs URB-20 (URB597, 20 mg/kg, i.p.) while
injection of VDM-11 decreased the contents of 5-HT in a dose-dependent fashion (Panel D; F (4, 45) = 208.677; P< 0.0001;
* vs Control/VEH, a vs
VDM-10 (VDM-11, 10 mg/kg, i.p.), € vs VDM-20 (VDM-11, 20 mg/kg, i.p.). All comparisons determined by a one-way ANOVA followed by Scheﬀe´’s
post hoc where P< 0.001 considered statistically diﬀerent.rebound period (Fig. 5, Panel D; F (4, 45) = 208.677;
P>0.05). From this studies, it is implied that URB597
showed more eﬃciency in promoting enhancement of 5-
HT compared to SR141716A whereas VDM-11 caused
reversed eﬀects.
In the last study, the AD contents during TSD were no
statistical diﬀerent among the experimental trials (Fig. 6,
Panel A; F (4, 45) = 1.067; P>0.05). Intriguing results
were found when animals received SR141716A after TSD
since the CB1 cannabinoid antagonist increased in a
dose-dependent fashion the contents of AD (Fig. 6, Panel
B; F (4, 45) = 6352.478; P<0.0001). Comparable results
were observed when URB597 was injected to rats sincethis compound caused an increase in a dose-dependent
fashion in AD levels after TSD (Fig. 6, Panel C;
F (4, 45) = 559.624; P<0.0001). Finally, the levels of AD
were decreased in a dose-dependent proﬁle after
VDM-11 injection (Fig. 6, Panel D; F (4, 45) = 438.322;
P<0.0001). Based in the data showed, we suggest that
URB597 displayed more eﬃciency in promoting the
increase of AD compared to SR141716A during the sleep
rebound period. However, diﬀering results were observed
after VDM-11 injections. Taken together, our results
indicate that the CB1 cannabinoid receptor, FAAH and
AMT might be involved in the control of homeostasis of
neurochemicals in response to sleep deprivation.
Fig. 6. Eﬀects of SR141716A, URB597 or VDM-11 (10, 20 or 30 mg/kg; i.p. each compound) on extracellular contents of adenosine collected after
prolonged waking. Panel A displays that levels of adenosine were increased after sleep deprivation (F (4, 45) = 1.067; P> 0.05). On the other hand,
injection of SR141716A increased in a dose-dependent fashion the levels of adenosine (Panel B; F (4, 45) = 6352.478; P< 0.0001;
* vs Control/
VEH, # vs SR-10 (SR141716A, 10 mg/kg, i.p.), & vs SR-20 (SR141716A, 20 mg/kg, i.p.). Moreover, URB597 induced similar eﬀects in adenosine
contents after sleep deprivation (Panel C; F (4,4 5) = 559.624; P< 0.0001;
* vs Control/VEH, ¥ vs URB-10 (URB597, 10 mg/kg, i.p.), – vs URB-20
(URB597, 20 mg/kg, i.p.). Lastly, injection of VDM-11 diminished the contents of adenosine in a dose-dependent fashion (Panel D; F (4, 45) =
438.332; P< 0.0001;* vs Control/VEH, a vs VDM-10 (VDM-11, 10 mg/kg, i.p.), € vs VDM-20 (VDM-11, 20 mg/kg, i.p.). All comparisons determined
by a one-way ANOVA followed by Scheﬀe´’s post hoc where P< 0.001 considered statistically diﬀerent.To study whether changes in neurochemicals
occurred at discrete time points or followed a consistent
trend across the sampling period, we analyzed the time
course of DA during TSD and the sleep recovery period
after injection of SR141716A. As expected, the levels of
DA were increased across TSD in experimental groups
(Fig. 7, Panel A). However, during sleep rebound
period, the extracellular contents of DA were enhanced
across 2 h post-administration of SR141716A (Fig. 7,
Panel B). Taken together, our results suggest that the
CB1 cannabinoid receptor antagonist might be involved
in the modulation of DA homeostasis after sleep
deprivation since this compound prolonged the
enhancement of DA during sleep recovery period.DISCUSSION
Although the presumably function of the endocannabinoid
system in sleep has been studied, further evidence is
needed regarding the role of this complex system in
homeostatic regulation of sleep. In this respective, sleep
is under control of circadian and homeostatic factors,
described in the two-process model of sleep–wake
regulation (Franken and Dijk, 2009; Schibler et al.,
2015; Borbely et al., 2016). Brieﬂy, the circadian process
represents the daily ﬂuctuation of the modulation of sleep
threshold levels. Complementary, the homeostatic pro-
cess symbolizes sleep drive that enhances when waking
is maintained beyond habitual bedtime and decreases
Fig. 7. Endogenous levels of dopamine during the total sleep deprivation (six samples taken at hourly intervals; Panel A) as well as dopamine
concentration across the sleep recovery period (4 samples taken at hourly intervals; Panel B). Due to that the experimental trails comprised 11
groups, and to avoid a tightened illustration, for demonstrative purposes in this given example, the graph includes only data of dopamine levels
corresponding to the following experimental groups: Sham, Vehicle, SR141716A (5 mg/kg), SR141716A (10 mg/kg), SR141716A (20 mg/kg).during the next sleep period, which is known as ‘‘sleep
rebound” (Deboer, 2009; Yasenkov and Deboer, 2012;
Curie et al., 2013; Mang and Franken, 2015).
To provide a further insight of the role of the
endocannabinoid system in sleep homeostasis
modulation, we report the eﬀects of the CB1
cannabinoid receptor blockade as well as the inhibition
of either FAAH or AMT in sleep homeostasis after a
short-lasting total sleep deprivation period. The
evidence from the present study shows that the CB1
cannabinoid receptor antagonist, SR141716A, blocked
the sleep rebound by inducing alertness in concordance
with previous reports. For example, preceding studies
have demonstrated that administrations of SR141716A
promote waking and diminish SWS and REMS
(Santucci et al., 1996; Murillo-Rodrı´guez et al., 2001,
2003). Furthermore, the CB1 cannabinoid receptor KO
mice show a reduction in SWS during sleep recovery per-
iod (Pava et al., 2014; Silvani et al., 2014). However, evi-
dence showing an apparent opposite modulatory role of
the CB1 cannabinoid receptor in sleep modulation has
been published as well. In this regard, injection of the
antagonist/inverse agonist AM281 of the CB1 cannabinoid
receptor immediately after TSD did not obstructed sleep
rebound (Pava et al., 2016). Moreover, SWS was
increased during the dark period after administrations of
higher dose of CP47497, a cannabinoid receptor agonist,
while reduction in this sleep stage was observed across
the light period (Pava et al., 2016). The intriguing but as
yet unexplained results that CB1 cannabinoid receptor
modulates sleep raises questions about the mechanism
of action implied. Nevertheless, evidence regarding the
role of the CB1 cannabinoid receptor in sleep rebound
has been addressed by others as well (Navarro et al.,
2003; Wang et al., 2011; Silvani et al., 2014). For
instance, the expression of the CB1 cannabinoid receptor
in thalamus and brainstem is signiﬁcantly higher during
the sleep rebound period (Wang et al., 2011). Takentogether, such ﬁndings reveal a striking phenomenon
regarding the putative role of the CB1 cannabinoid recep-
tor in sleep homeostasis control.
Diverse pieces of evidence suggest that the network
of the endocannabinoid system, which has been
partially studied, might govern the sleep–wake cycle.
Along with the CB1 cannabinoid receptor, the degrading
enzyme FAAH for anandamide (Seierstad and
Breitenbucher, 2008; Otrubova et al., 2011; Justinova
et al., 2015; Wei et al., 2015; Panlilio et al., 2016) also
appears to contribute in sleep modulation. Consistent with
this idea, expression of FAAH in several brain areas has
been described lower after sleep deprivation (Wang
et al., 2011). Furthermore, FAAH-KO mice display higher
values of SWS (Huitro´n-Rese´ndiz et al., 2004) while the
pharmacological inhibition of FAAH by administrations of
URB597 in rats promotes waking (Murillo-Rodrı´guez
et al., 2007, 2011). Conversely, it has been shown that
administrations of FAAH inhibitor AM3506 promote an
increase in SWS (Pava et al., 2016). According to the
authors, mice treated with a systemic injection of
AM3506 (10 mg/kg) during the dark period showed a sig-
niﬁcant enhancement in SWS whereas no eﬀects across
the light period were observed. Despite the tacit ﬁndings
in our study, the discrepancies between current results
and comparable studies might be addressed by method-
ological diﬀerences. For example, dosage, sleep analysis
procedure, species, pharmacological time administration,
among other variables might provide an alternative rea-
sonable explanation between opposite results. For
instance, Pava et al. (2016) used rotating disk paradigm
for sleep deprivation studies whereas in the current
report, gentle manipulation was handled. Diﬀerences in
techniques used for sleep deprivation have provided dif-
ferent outcomes in intensity of sleep rebound
(Rechtschaﬀen et al., 1999; Colavito et al., 2013; Pires
et al., 2016). Additionally, the pharmacodynamics
between the compounds might exert inﬂuence on the
eﬀects reported among comparable reports since
AM3506 is more potent than URB597 (Godlewski et al.,
2010; Panlilio et al., 2016). In spite of the diﬀerences in
experimental conditions between tantamount studies,
neurobiological basis might contribute as key determinant
of sleep control by FAAH since the exact mechanism of
action of FAAH in sleep homeostasis is still debated.
Nonetheless, the available data suggest that FAAH may
be implicated in sleep recovery. Indeed, future work is
needed to address an integrated portrait of the neurobio-
logical role of the FAAH in sleep homeostasis.
On the other side, it remains unclear how anandamide
is transported across the cell membrane. Though still
incomplete, the limited available data suggest that a
putative transporter controls the anandamide traﬃcking
(Cravatt et al., 2001; Kathuria et al., 2003; Makriyannis,
2014; Fezza et al., 2014; Batista et al., 2014; Nicolussi
and Gertsch, 2015). Regarding the role of AMT in sleep
modulation, this issue has been poorly studied. At this
date, scanty reports indicate that blocking AMT by VDM-
11 at the beginning of the lights-oﬀ period diminishes alert-
ness and enhances sleep (Murillo-Rodrı´guez et al., 2008).
In addition, microdialysis perfusion of AMT inhibitor
OMDM-2 into a sleep-related brain area such as the par-
aventricular thalamic nucleus increases sleep whereas
diminishes waking as well reduces the extracellular levels
of DA (Murillo-Rodrı´guez et al., 2013). Noteworthy, in the
current study when VDM-11 is administered after sleep
deprivation, rats displayed sleep rebound by enhancing
SWS and REMS. These ﬁndings suggest that blocking
AMT might increase anandamide signaling and likely
VDM-11 would not interfere with the homeostatic regula-
tion of sleep. It is unclear, however, whether AMT is able
of evoking control over sleep homeostasis.
In separate studies, we evaluated the impact of the
CB1 cannabinoid receptor blockade or the inhibition of
either FAAH or AMT in contents of neurochemicals after
prolonged waking. We would like to state that while
AcbC is a good target for sampling DA it might not be a
good option for NE, EP, 5-HT or AD sampling.
However, these neurochemicals have been collected
and measured from AcbC as previously reported (Salem
and Hope, 1999; Del Arco et al., 2008; Hernandez
et al., 2008; Rada et al., 2010; Cannazza et al., 2012;
Dobbs and Mark, 2012; Munari et al., 2013; Pajski and
Venton, 2013; Dautan et al., 2014). Thus, these evi-
dences indicate the trustworthy of our study. Overall, sys-
temic administration of SR141716A or URB597 before the
sleep rebound period enhanced dose-dependently the
extracellular levels of DA, NE, EP, 5-HT and AD whereas
VDM-11 caused opposite results. Remarkably, the con-
tents of DA were increased 2 h post-SR141716A injection
during sleep recovery period. How can we interpret this
data? Despite that we did not develop mechanicist exper-
iments, it is possible to draw the following hypothesis: An
interacting cross-talking between the endocannabinoid
and wake-related systems might be involved in described
eﬀects. This statement is based in the subsequent evi-
dence: First, it has been described the presence of the
CB1 cannabinoid receptor in wake-related brain areas
including hypothalamus and pons (Miederer et al., 2013;Soni et al., 2014). Second, there is an interactive relation-
ship between the CB1 cannabinoid receptor and DA sys-
tem (Degroot et al., 2006; Davis and Nomikos, 2008;
Martin et al., 2008; Kleijn et al., 2012; Dazzi et al.,
2014). Third, previous reports have shown that
SR141716A enhances NE contents (Tzavara et al.,
2001, 2003; Bedse et al., 2015). Fourth, there is evidence
regarding the interaction between the CB1 cannabinoid
receptor and AD system (Murillo-Rodrı´guez et al., 2003;
Cerri et al., 2014) suggesting that SR141716A would be
blocking the CB1 cannabinoid receptors present in cholin-
ergic neurons which are placed in basal forebrain, and
they are presumably responsible for AD release
(Blanco-Centurion et al., 2006; Huang et al., 2011).Taken
together, it might be reasonable to consider that
SR141716A or URB597 might activate the wake-related
neurotransmission systems and control sleep homeosta-
sis. Nevertheless, further studies are needed to clarify
whether the endocannabinoid system interacts with
wake-related components to control sleep homeostasis.
An alternative explanation implies that FAAH inhibition
might promote an endogenous accumulation of
monoamines as suggested by others (Solinas et al.,
2006; Murillo-Rodrı´guez et al., 2007, 2011; Cassano
et al., 2011; Bambico et al., 2016) or involving the activity
of the PPARa receptors as indicated (Melis et al., 2008;
Luchicchi et al., 2010; Bedse et al., 2015). Thus, it is likely
to speculate that the increase in contents of monoamines
or AD caused by URB597 during sleep rebound might be
via the engaging of PPARa receptors. To support this
idea, we have described that injection of Wy14643
(PPARa agonist) promoted W whereas decreased sleep.
Besides, this compound increased monoamines as well
as AD levels (Mijangos-Moreno et al., 2016). To
strengthen this alternative explanation, additional evi-
dence indicates that FAAH inhibition enhances contents
of oleoylethanolamide over anandamide levels (Fegley
et al., 2005). Importantly, oleoylethanolamide is the
endogenous ligand for PPARa receptors (Fu et al.,
2005; Campolongo et al., 2009; Bilbao et al., 2015) and
it has been demonstrated that injections of oleoylethano-
lamide promote waking (Murillo-Rodrı´guez et al., 2007,
2011). Since PPARs are found to be involved in energy
homeostasis (Tovar-Palacio et al., 2012; Tain et al.,
2015) they might be engaged in sleep homeostasis.
Therefore, URB597 may contribute to modulate sleep
homeostasis via activation of PPARa receptors by the
endogenous accumulation of oleoylethanolamide.
Despite this tempting scenario, no further evidence is
available regarding the possible link between FAAH and
PPARa receptors in sleep homeostasis.
Lastly, the injections of VDM-11 allowed the sleep
rebound in rats subjected to prolonged waking schedule.
Moreover, it is our understanding that the only available
data regarding the eﬀects of AMT inhibition in sleep-
related neurochemicals demonstrate that VDM-11
decreases DA levels as measured by HPLC means
(Murillo-Rodrı´guez et al., 2013). The results found in the
current study lead us to the following critical question:
What is the mechanism activated by VDM-11 that allowed
the sleep recovery in sleep-deprived rats? We cannot
answer this question yet, but it might be likely that VDM-
11 induces sleep via anandamide since it has been
described that VDM-11 promotes the endogenous accu-
mulation of this endocannabinoid (de Lago et al., 2004,
2005). In line with this idea, several pieces of evidence
supports that anandamide promotes sleep (Mechoulam
et al., 1997; Murillo-Rodrı´guez et al., 1998, 2001, 2003,
2011; Herrera-Solis et al., 2010; Rueda-Orozco et al.,
2010). Taken together, our data suggest that blocking
AMT does not interfere with sleep rebound. Nonetheless,
we cannot rule out the possibility that the eﬀects
described in our study might be mediated by concomitant
unknown mechanisms.CONCLUSION
Our results fortiﬁes the body of literature indicating that
administrations of either SR141716A or URB597
modulate sleep. Precisely, injections of both compounds
promoted wake-inducing eﬀects during sleep recovery
period whereas injections of VDM-11 induced sleep
across sleep recovery period. The present ﬁndings
remark that the animals treated with SR141716A or
URB597, increased alertness during sleep rebound
likely due to an endogenous accumulation of DA, NE,
EP, 5-HT or AD. However, VDM-11 allowed the display
of the sleep rebound in sleep-deprived rats by likely
decreasing the extracellular contents of wake-related
neurochemicals. Thus, for all data combined, the
presumably role of the endocannabinoid system in the
modulation of the sleep homeostasis after sleep
deprivation is highlighted. To add pieces to the puzzle of
the putative mechanism of action of SR141716A,
URB597 and VDM-11 in sleep homeostasis regulation, it
is worthy to note that the endocannabinoid system has
been described in astrocytes (Stella, 2010; Bosier et al.,
2013; K}oszeghy et al., 2015; Oliveira da Cruz et al.,
2016). Astrocytes have an important role in sleep home-
ostasis (Frank, 2011, 2013) with relevant functions by
releasing AD as gliotransmitter (Schmitt et al., 2012;
Nadjar et al., 2013; Hines and Haydon, 2014; O’Donnell
et al., 2015). Thus, taking into account all these ﬁndings,
CB1 cannabinoid receptor, FAAH or VDM-11 located in
astrocytes in sleep-related structures (K}oszeghy et al.,
2015; Kova´cs et al., 2016) might be playing an unde-
scribed role in sleep homeostasis. Indeed, the interac-
tions between the CB1 cannabinoid receptor, FAAH and
AMT placed in neurons and astrocytes during sleep
homeostasis remain to be described. Further investiga-
tions regarding this issue would be basis of clinical
research aimed to explore the pharmacological manipula-
tion of the endocannabinoid system with potential thera-
peutical beneﬁts in sleep homeostatic disorders.REFERENCES
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